Arrowgrass Capital Partners (US)’s Neurocrine Biosciences NBIX Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-102,200	Closed	-$8.63M	–	259
2019 Q2	$8.63M	Buy	+102,200	New	+$8.39M	0.2%	134
2018 Q2	–	Sell	-84,002	Closed	-$6.97M	–	216
2018 Q1	$6.97M	Buy	84,002 +9,702	+13%	+$819K	0.24%	63
2017 Q4	$5.76M	Buy	+74,300	New	+$5.07M	0.06%	288
2015 Q2	–	Sell	-40,000	Closed	-$1.59M	–	551
2015 Q1	$1.59M	Buy	+40,000	New	+$1.43M	0.02%	282

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s NBIX Position: Q3 2019 in Review

Arrowgrass Capital Partners (US) sold out of Neurocrine Biosciences (NBIX) in Q3 2019, closing a stake of 102,200 shares — an estimated $8.63M sold.

Arrowgrass Capital Partners (US) first reported a position in NBIX in Q1 2015 and held it in 4 quarters. The position peaked at $8.63M in Q2 2019. 333 funds tracked by Wall St. Rank hold NBIX as of Q3 2019.

Arrowgrass Capital Partners (US) reported no remaining Neurocrine Biosciences position as of Q3 2019 after selling out during the quarter.
Arrowgrass Capital Partners (US) sold 102,200 Neurocrine Biosciences shares in Q3 2019, an estimated $8.63M.
Arrowgrass Capital Partners (US) first reported a position in Neurocrine Biosciences in Q1 2015 and held it in 4 quarters.
Arrowgrass Capital Partners (US)'s Neurocrine Biosciences position peaked at $8.63M in Q2 2019.
333 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2019.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q3 2019, filed 14 Nov 2019.